SCHEMBL12848449

SCHEMBL12848449

Cn1nnc(N2CCC3=C(C2)c2ncc(NC(=O)c4c(F)cccc4F)nc2CCC3)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RORC P51449 4/20 0.36
▸ KMT2A Q03164 3/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ HTR1F P30939 4/20 0.33
▸ RAB9A P51151 3/20 0.33
▸ NPC1 O15118 2/20 0.33
▸ HTR1A P08908 1/20 0.33
▸ HTR1B P28222 1/20 0.33
▸ HTR2A P28223 1/20 0.33
▸ HTR2C P28335 1/20 0.33
▸ HTR2B P41595 1/20 0.33
▸ MAPT P10636 2/20 0.33
▸ IL2 P60568 1/20 0.32
▸ KDM4E B2RXH2 2/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ CHRM5 P08912 1/20 0.32
▸ DRD5 P21918 1/20 0.32
▸ HTR1D P28221 1/20 0.32
▸ HTR1E P28566 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12848849 0.87 HTR1F (0.40) KMT2AHTR1FRAB9ANPC1MAPT
SCHEMBL12848842 0.83 — —
SCHEMBL12848445 0.81 MEN1 (0.38) RORCKMT2AMEN1HTR1FRAB9A
SCHEMBL3825366 0.78 IL2 (0.44) RORCKMT2AMEN1HTR1FRAB9A
SCHEMBL5005018 0.77 IL2 (0.41) RORCKMT2AMEN1HTR1FRAB9A
SCHEMBL4999197 0.76 IL2 (0.41) RORCKMT2AMEN1HTR1FRAB9A
SCHEMBL3826864 0.76 IL2 (0.38) RORCKMT2AMEN1HTR1FRAB9A
SCHEMBL5019662 0.76 IL2 (0.40) RORCKMT2AMEN1HTR1FRAB9A
SCHEMBL12848851 0.75 ADORA2A (0.33) RORCKMT2AMEN1RAB9ANPC1
SCHEMBL12848841 0.75 MAPT (0.37) KMT2ARAB9ANPC1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110052643-A1 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2011-03-03 — — US disclosed
WO-2009089305-A1 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2009-07-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110052643-A1 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES TSLP, NFATC1, IL5 RORC 28/4885KMT2A 3424/4885MEN1 4414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback